API Upswing & Margin Expansion—The FY27 Inflection Point
After Q1's margin surprise, VIYASH heads into Q2 riding strong double-digit growth and the first full contribution from BioForLife. Street sees 37% upside; the quarter tests if the group can sustain 20%+ EBITDA while digesting European acquisition.
What to Expect in Q2 FY27
~₹950–1,000 Cr
Implies 17–20% YoY growth; Q1 was ₹946.4 Cr (+19.5% YoY). Management expects double-digit FY27 growth on track.
~20–22%
Q1 delivered 21.6%; guidance targets 20–22%. Swing factor: API mix and BioForLife integration cost.
~₹80–90 Cr
Q1 PAT ₹79.3 Cr (+114.9% YoY). Depends on margin carry-through and one-time deal costs.
~₹35–45 Cr revenue
Acquisition closed Oct 1; roughly 50 days in Q2. Run-rate ~€16.98M annually (~₹145 Cr).
A strong Q2 print would confirm Q1's margin expansion is structural, not a one-off: revenue at or above ₹1,000 Cr with EBITDA margin holding 21%+, and PAT tracking the 100%+ growth seen in Q1 (reflecting operating leverage and lower tax). A weak print would raise questions: revenue below ₹950 Cr (signaling demand softness in the core API segment), EBITDA margin <20% (integration costs heavier than expected, or unfavorable API mix), or PAT growth stalling despite top-line beat (pricing pressure or M&A drag).
On Track for FY27 Targets?
Yes—so far. VIYASH guided to ₹4,000 Cr revenue and 20% EBITDA margin by FY27 (later confirmed to be FY27, not FY28). Q1 annualized run-rate is ~₹3,800–3,900 Cr; adding BioForLife's full-year ~₹145 Cr gets close to ₹4,000 Cr. The real test: margin hold-through as the company scales the API segment and absorbs BioForLife. Q1's 59% EBITDA growth on 19.5% revenue growth is bullish on leverage, but Q2 will show if it sticks.
Street View
Since Last Quarter: The Moves
BioForLife Closed (Oct 1): The ₹188 Cr acquisition completed, giving VIYASH a foothold in Italy's companion animal health market (80%+ veterinary clinic penetration, 85–90 SKUs). Contributes roughly 50 days to Q2 P&L. Upside: geographic diversification and high-margin generics; downside: integration costs and currency exposure. Vietnam Subsidiary Incorporation (Oct 30): Alivira (VIYASH's animal health arm) incorporated Alivira Vietnam Company Limited—early-stage geographic play, no immediate P&L impact but flagged as expansion strategy.
Ownership Shifts (Aug–Oct): Promoters CA Harbor Investments and CA Hull Investments collectively sold 11.53% of the company on Aug 26–27 at ~₹265–270 via open market deals—a material reduction in promoter stake (from ~61% to lower 50s % range). White Oak Capital sold another 2% stake on Oct 17. Market read it as profit-taking but no negative signals on operations. FII buying picked up (Kotak Mutual Fund, innovation funds bought in Aug block deals), offset partially by DII selling. Net-net: governance questions quieted by Q1 margin beat.
Management Change (Oct 20): Dr. Mallikharjuna Rao Nagineni appointed Senior Vice President, HR, as part of a reshuffle—routine organizational move, no strategic impact flagged.
What to Watch on Nov 13
1 · API Segment Revenue & Growth
Management called Q2 the 'best-ever quarter' for APIs. Look for the actual revenue and growth rate. A miss here (e.g., <15% YoY growth or margin compression) would contradict the on-plan narrative.
2 · BioForLife Day-1 Margin
How much revenue did BioForLife contribute in ~50 days, and at what margin? A low-margin integration (or one-time costs) could pull down consolidated EBITDA margin below 20%, signaling execution risk.
3 · Organic vs. Inorganic Split
Management should clarify organic growth ex-BioForLife. If organic growth is <15%, it suggests API momentum is softer than Q1, even if consolidated growth looks healthy due to BioForLife add.
4 · FY27 Guidance Confirmation / Update
Will VIYASH reaffirm ₹4,000 Cr FY27 revenue / 20% EBITDA margin, or revise? Any downward tweak on margin target (e.g., to 19%) or revenue (to ₹3,900 Cr) would compress the bull case.
5 · Tax Rate & Other Income
Q1 PAT growth of 115% outpaced EBITDA growth of 59%, driven partly by lower tax. Is this sustainable, or was Q1 a tax one-off? Any change in tax rate or finance costs matters for earnings momentum.
The Setup in One Take
VIYASH is at an inflection: Q1 FY27 proved that the merger playbook works (19.5% revenue growth + 59% EBITDA growth = margin expansion), and the Street has priced in a 37% re-rating. Q2 is the verdict on whether that margin beat was structural or temporary. The company has two narratives running in parallel—organic API strength (flagged as best-ever) and inorganic BioForLife upside (European footprint, high-margin generics)—but also carries integration risk and promoter selling-induced governance questions. Execution on both fronts is non-trivial.
Watch the API revenue growth rate and EBITDA margin most closely; if VIYASH delivers 20%+ EBITDA on organic growth >15%, the Street target of ₹326 looks within reach. A miss on either (organic growth <15% or margin <20%) would argue for a re-rate lower. BioForLife's Q2 contribution is gravy if the core story holds; it's a distraction if the API segment falters.
Viyash Q2 FY27: Consolidated PAT ₹84.7 Cr, ~16% Like-for-Like Growth as Margins Compress
PAT +331.89% YoY · revenue +133.01% · margins compressing
₹987.94 Cr
+133.01% YoY
₹84.65 Cr
+331.89% YoY
8.47%
+3.9pp YoY
₹1.74
Viyash Scientific (formerly Sequent Scientific) posted consolidated revenue of ₹987.94 Cr and PAT of ₹84.65 Cr for Q2 FY27, up 4.4% and 6.8% sequentially over Q1 FY27's ₹946.36 Cr/₹79.29 Cr. The headline YoY jump against our database's year-ago base (₹423.99 Cr revenue, ₹19.60 Cr PAT) looks explosive at +133%/+332%, but that comparison predates the Composite Scheme of Amalgamation that folded SeQuent Research, Viyash Life Sciences and several other group entities into the listed company under pooling-of-interest accounting. The filing's own restated year-ago column — ₹850.30 Cr revenue, ₹72.90 Cr PAT — is the real like-for-like base, putting organic YoY growth at a much steadier ~16.2% on revenue and ~16.1% on PAT (adjusted). That is roughly in line with, or modestly ahead of, management's FY27 guidance of 13-15% API segment growth, though this is a total-company read rather than segment-specific.
Q2 FY-2027 vs prior quarters
Margins moved the other way: operating margin (EBITDA/revenue, ex-other income) slipped to 16.7% from 18.85% in Q1 FY27 and from a restated 20.37% a year ago, even as net profit margin held roughly flat at 8.47% (vs 8.31% QoQ, 8.50% restated YoY) — tax and finance-cost ratios offset most of the operating squeeze. The compression traces mainly to cost of materials rising to 44.4% of revenue from 42.5% in Q1 FY27, plus a step-up in employee costs to 18.7% of revenue from 17.2%; part of that increase is the non-cash ESOP charge of ₹37.7 Cr this quarter (₹56.3 Cr for H1) under the new Scheme 2026 ESOP, following the February 2026 grant of 1.31 crore options.
The stock went into the print at ₹255.32, up 9.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹1.74 vs ₹1.51 in Q1 FY27
FY27 overall API growth 13–15% double-digit; companion animal formulation targeting 20%+ expansion; EV acquisition (BioForLife Italy) to close next few months, 18–24 month registration cycle. ₹250–300 Cr capex this year. 1 billion revenue target by FY32 at 18% CAGR.
— This quarter: met
No street preview or consensus estimate specific to this quarter turned up in search — full-year FY27 consensus (revenue ~₹3,900 Cr, +14%) exists on aggregator sites but nothing quarter-specific, so vs-street is marked unknown rather than guessed. Management's own press release was not available in the context to cross-check framing. The quarter's corporate actions tie into the guided EV/companion-animal push: the BioForLife Italia S.r.l. acquisition (flagged in the prior concall as pending) completed on October 1, 2026 for the full equity stake, and the company incorporated a new Vietnam subsidiary on November 2, 2026, both consistent with the stated geographic and portfolio expansion plan. A Senior VP-HR change and a 2% stake sale by White Oak Capital occurred in the quarter but carry no direct read-through to the P&L.
W1
Whether operating margin recovers toward the 19-20% range seen in Q1 FY27 and the restated year-ago quarter, or the 16-17% level persists as the post-merger/post-ESOP baseline
W2
Like-for-like growth trajectory against management's guided FY27 API growth of 13-15% and companion-animal formulation growth of 20%+, tracked off the ~16% H1 like-for-like base
W3
Integration contribution and costs from BioForLife Italia (completed Oct 1, 2026) and the new Vietnam subsidiary in upcoming quarters
Clean digital filing, column headers unambiguous, arithmetic ties exactly on both statements. Consolidated PAT of ₹84.65 Cr includes NCI of ₹8.48 Cr (owners' PAT ₹76.17 Cr). No exceptional items this quarter vs a ₹1.70 Cr amalgamation-related exceptional loss in the restated year-ago quarter. Reported YoY comps vs our DB base (pre-merger ₹423.99 Cr revenue/₹19.60 Cr PAT) are inflated by the Scheme of Amalgamation (pooling-of-interest restatement effective 16-Dec-2025); the filing's own restated year-ago column (₹850.30 Cr revenue/₹72.90 Cr PAT) is the true like-for-like base.